Warning: The NCBI web site requires JavaScript to function. more...

An official website of the United States government

Here's how you know

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Account

Logged in as:
username

Dashboard
Publications
Account settings
Log out

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

MeSH

NLM Controlled Vocabulary

Search database

Search term

Limits
Advanced
Help

Full

Format

Full
Full (text)
Summary
Summary (text)

Send to:

Choose Destination

File
Clipboard
Collections

Format

Afatinib

A quinazoline and butenamide derivative that acts as a tyrosine kinase inhibitor of epidermal growth factor receptors (ERBB RECEPTORS) and is used in the treatment of metastatic NON-SMALL CELL LUNG CANCER.

Year introduced: 2019 (2007)

PubMed search builder options

Subheadings:

administration and dosage
adverse effects
agonists
analogs and derivatives
analysis
antagonists and inhibitors
blood
cerebrospinal fluid
chemical synthesis

chemistry
classification
economics
history
immunology
isolation and purification
metabolism
pharmacokinetics

pharmacology
poisoning
radiation effects
standards
supply and distribution
therapeutic use
toxicity
urine

Restrict to MeSH Major Topic.

Do not include MeSH terms found below this term in the MeSH hierarchy.

Tree Number(s): D02.065.132, D03.633.100.786.188

MeSH Unique ID: D000077716

Registry Number: 41UD74L59M

Entry Terms:

(2E)-N-(4-(3-Chloro-4-fluoroanilino)-7-(((3S)-oxolan-3-yl)oxy)quinoxazolin-6-yl)-4-(dimethylamino)but-2-enamide
BIBW-2992-MA2
BIBW 2992 MA2
BIBW-2992MA2
BIBW 2992MA2
BIBW2992 MA2
Afatinib Maleate
BIBW 2992
BIBW2992
BIBW-2992
Gilotrif
Afatinib Dimaleate

Pharmacologic Action: